

HBV X gene point mutations are associated with the risk of hepatocellular carcinoma: A systematic review and meta-analysis

YULAN WANG, LI ZENG and WEIQING CHEN

Department of Gastroenterology and Respiratory Medicine, Chongqing Cancer Hospital
and Institute and Cancer Center, Chongqing 400030, P.R. China

Received May 7, 2015; Accepted November 16, 2015

DOI: 10.3892/mco.2016.847

Abstract. Previous evidence suggests that the accumulation of the hepatitis B virus (HBV) X gene region point mutations may be associated with the development of hepatocellular carcinoma (HCC). However, the pathogenesis of HCC remains to be elucidated. The aim of the present meta-analysis was to investigate the association between the HBV X gene point mutations and the risk of HCC. Studies were collected regarding the association between HBV X gene point mutations and the risk of HCC, which were identified in PubMed, EMBASE and China National Knowledge Infrastructure databases. The results were evaluated by use of odds ratios (ORs) and its 95% confidence intervals (CIs), which were pooled by random or fixed effects. A total of 11 studies involving 2,502 patients were included in this meta-analysis. Statistical summary ORs of HBV X gene point mutations were obtained for T1653 (OR, 3.11; 95% CI, 2.22-4.36), V1753 (OR, 2.55; 95% CI, 1.66-3.92), and T1762/A1764 (OR, 4.49; 95% CI, 2.86-7.07). HBV X gene point mutations T1653, V1753 and T1762/A1764 could increase the risk of HCC significantly, particularly the T1762/A1764 double mutations. These mutations may be predictive for hepatocarcinogenesis. However, these results of the meta-analysis should be treated carefully due to a low level of evidence.

Introduction

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide, which is a serious risk to human health (1,2). However, the pathogenesis of HCC has not been fully elucidated. Hepatitis B virus (HBV) chronic infection is considered one of the major risk factors for the development of HCC (3-5).

Correspondence to: Professor Weiqing Chen, Department of Gastroenterology and Respiratory Medicine, Chongqing Cancer Hospital and Institute and Cancer Center, 181 Hanyu Road, Chongqing 400030, P.R. China
E-mail: chenwq20140809@163.com

Key words: hepatitis B virus X gene, hepatocellular carcinoma, meta-analysis, point mutation

The HBV genome is an incomplete double-stranded circular structure, containing 4 open reading frames (ORF): S, C, P and X (6,7). ORF region mutations could alter viral replication and virulence force, which lead to a persistent virus infection and severe liver cell damage, and eventually result in the development of HCC (8,9). The precore region encodes the hepatitis B e-antigen (HBeAg), which has been associated with an increased risk of HCC statistically. Certain studies have shown that HBV X gene point mutations can affect the expression of HBeAg and increase the viral replication capacity (8,10,11). In recent years, the association between HBV mutations and the incidence of HCC has focused on the X gene region, the former C gene region and pre-S gene region, and the X gene region is the most important.

Previously, certain studies have identified that the X gene region T1653, V1753, T1762/A1764 and other point mutations may be associated with persistent HBV infection and the development of HCC (6,10-13). However, there remains certain controversy and further research is required. Therefore, the present meta-analysis was performed to investigate the association between HBV X gene point mutations and the development of HCC systematically and comprehensively.

Materials and methods

Search strategy. Two authors (Wang and Zeng) searched PubMed, EMBASE, the Cochrane Library and Chinese National Knowledge Infrastructure for the relevant studies. The key words included: 'Hepatitis B virus X gene', 'mutation', 'liver cancer or hepatocellular carcinoma'. The searches were limited to human subjects. Language restriction was not imposed on the search process. In addition, the reference lists of the included studies were checked manually for other potentially eligible studies. This process was repeated until no additional associated studies could be identified.

Inclusion criteria. The inclusion criteria included: i) Study design for the prevalence of case-control; ii) the diagnoses of chronic hepatitis B, liver cirrhosis and HCC were according to the guidelines of the American Association for the Study of Liver Diseases (14); iii) all HBsAg-positive patients were infected with HBV >2 years and the HBV DNA level was in accordance with the test standard; and iv) the reported outcomes of patients was HCC.

Exclusion criteria. The exclusion criteria included: i) Patients with HCV, HDV or human immunodeficiency virus infection; ii) patients with alcoholic liver disease, autoimmune disease or drug-induced liver disease; iii) patients with antiviral treatment; iv) if similar research was reported by the same author, only the recent study or high-quality study was included in this analysis.

Data extraction and quality evaluation. Data extraction and quality evaluation of studies were conducted by 2 independent authors (Wang and Chen). The extracted data included first author, publication year, country, study design, quality score, cases of patients (number of events and total patients), age, gender, alanine aminotransferase and HBV DNA level, genotypes, mutation sites and detection method. The evaluation standard was in accordance with the methods of the study by Liu *et al* (15). Discussion or a third investigator aided in solving any disagreements.

Statistical analysis. The odds ratios (ORs) with 95% confidence intervals (CIs) of binary end points were analyzed. Heterogeneity was checked using χ^2 test, P-values and I^2 . The random effects model was used when $P < 0.1$; otherwise the fixed effects model was used when $P \geq 0.1$. Sensitivity analysis was conducted by eliminating one study in turn in the analysis. Potential publication bias was evaluated by visual inspection of the Begg funnel plots in which the log ORs were plotted against their standard errors. All the data were calculated by RevMan 5.0 software (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration).

Results

Study characteristics. According to the inclusion and exclusion criteria of the literature, 11 studies involving 2,502 patients were included in this meta-analysis, of whom 2,801 had HCC. These studies included 1 study in Chinese and 10 in English (6,11,13,16-23). A detailed flow chart explaining the inclusion of studies is shown in Fig. 1. The extracted information from the studies included: i) The publication year of the studies was between 1999 and 2013; ii) the study design were case-control studies; iii) the countries of the studies included mainland China, Hong Kong, South Korea and Thailand. A summary of the 11 included studies is shown in Table I. The details of the quality criteria based on factors are listed in Table II.

Meta-analysis. All 11 studies involving 2,502 patients reported that the relevant outcome of the T1653, V1753 and T1762/A1764 point mutations were associated with the risk of HCC. The results of the meta-analysis showed that T1653 (OR, 3.11; 95% CI, 2.22-4.36) (Fig. 2), V1753 (OR, 2.55; 95% CI, 1.66-3.92) (Fig. 3) and T1762/A1764 (OR, 4.49; 95% CI, 2.86-7.07) (Fig. 4) increase the risk of HCC.

Subgroup analysis. The summary ORs for HBV X gene mutations were explored by HBeAg status, country and quality score. The summary OR of the T1762/A1764 double mutations in HBeAg (+) group were lower compared to the HBeAg (-) group, whereas the T1653 and V1753 mutations




Figure 1. Flow diagram of the relevant studies included in the meta-analysis. HCV, hepatitis C virus.

were higher. There is no significant difference in the results between subgroup and overall analyses except for the V1753 point mutation for the risk of HCC in patients from Korea. The result suggested that there was no statistically significant associations between the V1753 mutation and the risk of HCC in Korean patients (OR, 1.25; 95% CI, 0.69-2.26) (Table III). The summary ORs for T1653, V1753 and T1762/A1764 increased with decreasing study quality score (Table III).

Sensitivity analysis and publication bias. The effect of a single study on the overall pooled analyses was investigated by sensitivity analysis to evaluate the heterogeneity of each study. There were no significant influences observed when one study was removed each turn. The funnel plot showed an asymmetrical distribution of these studies, indicating that publication bias existed in these results regarding an association between T1653 (Fig. 5A), V1753 (Fig. 5B) and T1762/A1764 (Fig. 5C) point mutations and the risk of HCC.

Discussion

Meta-analysis is regarded as a qualitative and quantitative tool to solve those problems that remain controversial in clinical settings. The results of the meta-analysis were the highest level of evidence. The debate on the association between HBV gene mutations and development of HCC is ongoing. Recently, a series of studies on this subject have been published. Therefore, the present meta-analysis was performed and the results showed that T1653, V1753 and T1762/A1764 mutations could significantly increase the risk of HCC, particularly the T1762/A1764 double mutations.

HBV chronic infection is the most important risk factor for the development of HCC (24). Lin *et al* (25) considered that the transactivation function of the carboxyl terminus of the HBV X protein would regulate HBV DNA replication and transcription of liver cell proliferation and differentiation. As well as T1653, V1753 and T1762/A1764 mutations are all located in the carboxyl terminus region of the HBV X protein.

Table I. Characteristics and clinical data of the studies included in the meta-analysis.

Authors (year)	Country	Design	Quality score	E/C	Age, years	Gender (m/f)	ALT level (U/l)	HBV DNA (log copy/ml)	HBsAg (+) patients (%)	Genotype	Mutation sites	Detection method	Refs.
Takahashi <i>et al</i> (1999)	Japan	PCC	6-10	58/271	NA	NA	NA	NA	108 (37.6)	C	T1653, V1753, T1762, A1764, T1762/A1764	Sequencing	(16)
Tanaka <i>et al</i> (2006)	Japan/HK	PCC	≥10	148/180	50.2±10.7	261/69	46 (8-773)	5.4±1.4	109 (33.2)	C1, C2	T1653, V1753, T1762/A1764, V1765, A1896, A1899	Sequencing	(17)
Shinkai <i>et al</i> (2007)	Japan	PCC	≥10	80/80	55±8	135/25	85±133	5.7±1.4	60 (37.5)	C2	T1653, C1479, T1485, H1499, A1613, V1753, T1762/A1764, A1896	Sequencing	(13)
Wang <i>et al</i> (2007)	China	PCC	≤6	47/164	49.8±11.6	176/35	63.9±41.6	NA	112 (53.1)	Ba, C1, C2	T1653, V1753, T1762/A1764, T1856, T1858, A1896, A1898, A1899	Sequencing	(18)
Kim <i>et al</i> (2008)	Korea	PCC	6-10	60/124	45.9±17.3	134/50	90.8±132.1	NA	115 (62.5)	C	T1653, V1753, T1762/A1764	Sequencing	(19)
Kim <i>et al</i> (2009)	Korea	PCC	≥10	135/135	44.3±7.9	224/46	NA	3.45±3.8	76 (28.1)	C2	T1653, A1689, V1753, T1762/A1764, T1846, A1850, C1858, A1896	Sequencing	(6)
Choi <i>et al</i> (2009)	Korea	PCC	≤6	42/46	57.3±9.3	57/31	89.8±110.5	6.2±1.5	39 (44.3)	C2	M1385, A1485, B1499, B1574, A1613, T1631, T1653, V1753, T1762/A1764	Sequencing	(20)
Tangkijvanich <i>et al</i> (2010)	Thailand	PCC	≥10	60/60	55.7±9.8	104/16	161.1±116.9	5.9±1.4	32 (30)	B, C	A1613, T1653, V1753, T1762/A1764, T1766/A1768, C1858C	Sequencing	(21)
Shi <i>et al</i> (2013)	China	PCC	≤6	43/55	58.0±9.58	63/32	NA	4.67±0.91	46 (47.9)	NA	A1440, C1467, A1479, T1485, T1653, V1753, T1762/A1764	Sequencing	(11)
Li <i>et al</i> (2013)	China	PCC	6-10	102/105	NA	NA	NA	NA	NA	C2	T1653, V1753, T1762, A1764, T1766, A1768	Sequencing	(22)
Lyu <i>et al</i> (2013)	Korea	PCC	6-10	318/234	55 (30-74)	452/100	37 (9-774)	4.09±2.39	271 (49.1)	C2	T1653, V1753, T1762/A1764, A1896	Sequencing	(23)

ALT, alanine aminotransferase; E/C, no. of experiments/no. of controls; HBsAg, hepatitis B e-antigen; HBV, hepatitis B virus; m/f, male/female; NA, not available; PCC, prevalence case-control.

Table II. Details of the quality criteria for studies included in the meta-analysis.

Quality parameter	Score		
	0	1	2
Study design	Cohort or nested case-control	Incidence case-control	Prevalence case-control
Sample size of cases	<50	50-100	≥100
Source of samples	None	1 hospital	≥2 hospitals
Mutation detection method	None	Others	DNA sequencing
Matching of cases and controls			
(1)	None	Age or gender	Age and gender
(2)	None	HBeAg or genotype	HBeAg and genotype

HBeAg, hepatitis B e-antigen.




Figure 2. Forest plot for the odds ratios of T1653 for the risk of HCC. HCC, hepatocellular carcinoma; CI, confidence interval; M-H, Mantel-Haensze.




Figure 3. Forest plot for the odds ratios of V1753 for the risk of HCC. HCC, hepatocellular carcinoma; CI, confidence interval; M-H, Mantel-Haensze.

Kim *et al* (19) suggested that T1653, V1753 and T1762/A1764 mutations would change the sequence of HBV X protein amino acids, further leading to the activation of proto-oncogenes and inactivation of the tumor suppressor gene, eventually causing the occurrence of HBV-related HCC. However, the mechanism of how the point mutations of HBV X gene region affect the biological function of HBV X protein remains to be elucidated in further studies.

Liu *et al* (15) considered that the HBeAg status would affect the point mutation type of the HBV X gene and development of HCC. Previous studies suggested that the expression of HBeAg is often significantly correlated with immune evasion and acted as an indicator of active viral replication (26,27). In the subgroup analysis, data on the HBeAg status was extracted, which was a potential confounder, and identified that T1762/A1764 double mutations could decrease HBeAg

Table III. Subgroup analyses based on the main characteristics of the included studies.

Characteristics	T1653			V1753			T1762/A1764		
	T/P	OR (95% CI)	Model	T/P	OR (95% CI)	Model	T/P	OR (95% CI)	Model
HBeAg									
+	5/392	3.25 (1.87-5.66)	Fixed	5/392	2.50 (1.52-4.12)	Fixed	6/536	3.15 (2.03-4.89)	Fixed
-	5/741	2.56 (1.78-3.68)	Fixed	5/741	1.84 (1.32-2.58)	Fixed	6/911	5.50 (2.64-11.46)	Fixed
Country									
China	3/513	3.23 (1.80-5.79)	Fixed	3/513	5.17 (3.28-8.13)	Fixed	3/513	5.99 (2.17-16.53)	Random
Japan	3/775	3.78 (1.52-9.41)	Random	3/775	2.93 (2.11-4.06)	Fixed	3/775	4.27 (2.68-6.80)	Fixed
Korea	4/1,094	2.50 (1.77-3.54)	Fixed	4/1,094	1.25 (0.69-2.26)	Random	4/1,094	3.58 (1.46-8.79)	Random
Thailand	1/120	2.75 (1.04-7.29)	NA	1/120	2.51 (1.14-5.52)	NA	1/120	6.19 (2.42-15.83)	NA
Quality score									
>6	8/2,108	3.05 (2.10-4.42)	Random	8/2,108	2.14 (1.39-3.28)	Random	8/2,108	3.66 (2.30-5.81)	Random
≤6	3/394	3.11 (1.74-5.59)	Fixed	3/394	5.18 (2.98-9.02)	Fixed	3/394	9.60 (5.14-17.93)	Fixed

HBeAg, hepatitis B e-antigen; NA, not available; OR, odds ratio; T/P, no. of trials/no. of patients.




Figure 4. Forest plot for the odds ratios of T1762/A1764 for the risk of HCC. HCC, hepatocellular carcinoma; CI, confidence interval; M-H, Mantel-Haensze.




Figure 5. Funnel plot regarding the publication bias of (A) T1653, (B) V1753 and (C) T1762/A1764 for the risk of hepatocellular carcinoma. OR, odds ratio; SE, standard error.

expression. However, a large number of studies showed that T1762/A1764 double mutations could enhance the virus replication. The contradiction indicated that the decrease of

HBeAg expression did not equate to an improved development of HCC. Persistent chronic HBV infection may be due to HBV immune escape, which further aggravates the condition

of patients and eventually results in HCC (28,29). Li *et al* (22) reported that T1762/A1764 double mutations could not predict the development of HCC. However, the present study identified that double mutations were more closely associated with the risk of HCC compared to T1653 or V1753 alone. Therefore, the combined mutations could lead to a higher incidence of liver cancer and improve the predictability of HCC.

The present findings showed that the summary ORs for T1653, V1753 and T1762/A1764 were higher in the low-quality compared to the high-quality studies. Potential confounders may have an important role in evaluating HBV mutations and the risk of HCC in low-quality studies. Yin *et al* (30) suggested that the average age of the patients with chronic hepatitis B was 10 years younger than that of the patients with HCC. Additionally, Yang *et al* (31) suggested that HBV mutations accumulated with increasing age. Therefore, the association between the HBV X gene point mutations and risk of HCC was more likely to be overestimated in the confounder-unmatched, low-quality studies.

The main characteristics embodied in the present study were: i) The association between HBV X gene mutations and development of HCC among various studies examined systematically and comprehensively, in order to have an improved understanding for the effect of HBV X protein on development of HCC; ii) a series of subgroup analyses were conducted to explore the effect of potential confounding factors on the development of HCC; and iii) the results suggested that these point mutations could be used as molecular markers of the risk of HCC. The limitations of the study were: i) The age, gender, genotype and other confounding factors could not be matched fully and the existence of various offsets requires further information and data to be confirmed; ii) only 3 HBV X gene mutations were analyzed in the meta-analysis, and there may be other gene mutations that affect the HBV X protein biological function as well as V1674, T1766 and A1768 mutations; and iii) the included studies were all observational case-control studies, as experimental studies could not be conducted in humans.

In the future, the mechanism of the HBV X gene region point mutations should focus on the biological function of the HBV X protein and the association with the development of HCC. In order to improve the prediction for HCC risk and reduce or even avoid the development of HCC, quicker and easier methods should be developed for the detection of HBV gene mutations.

Acknowledgements

The authors would like to thank Dr Longkun Li for providing methods of data analysis.

References

- Cazzagon N, Trevisani F, Maddalo G, *et al*: Italian Liver Cancer (ITA.LI.CA) Group: Rise and fall of HCV-related hepatocellular carcinoma in Italy: A long-term survey from the ITA.LI.CA centres. *Liver Int* 33: 1420-1427, 2013.
- Fares N and Peron JM: Epidemiology, natural history, and risk factors of hepatocellular carcinoma. *Rev Prat* 63: 216-217, 220-212, 2013 (In French).
- Matsuda Y and Ichida T: Impact of hepatitis B virus X protein on the DNA damage response during hepatocarcinogenesis. *Med Mol Morphol* 42: 138-142, 2009.
- Rawat S, Clippinger AJ and Bouchard MJ: Modulation of apoptotic signaling by the hepatitis B virus X protein. *Viruses* 4: 2945-2972, 2012.
- Bouchard MJ and Navas-Martin S: Hepatitis B and C virus hepatocarcinogenesis: Lessons learned and future challenges. *Cancer Lett* 305: 123-143, 2011.
- Kim JK, Chang HY, Lee JM, Baatarxuu O, Yoon YJ, Park JY, Kim Y, Han KH, Chon CY and Ahn SH: Specific mutations in the enhancer II/core promoter/precure regions of hepatitis B virus subgenotype C2 in Korean patients with hepatocellular carcinoma. *J Med Virol* 81: 1002-1008, 2009.
- Liu L, Li Y, Zhang S, Yu D and Zhu M: Hepatitis B virus X protein mutant upregulates CENP-A expression in hepatoma cells. *Oncol Rep* 27: 168-173, 2012.
- Tu H, Bonura C, Giannini C, Mouly H, Soussan P, Kew M, Paterlini-Bréchet P, Bréchet C and Kremsdorf D: Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. *Cancer Res* 61: 7803-7810, 2001.
- Yeh CT, Shen CH, Tai DI, Chu CM and Liaw YF: Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma. *Oncogene* 19: 5213-5220, 2000.
- Kaneko M, Uchida T, Moriyama M, Arakawa Y, Shikata T, Gotoh K and Mima S: Probable implication of mutations of the X open reading frame in the onset of fulminant hepatitis B. *J Med Virol* 47: 204-208, 1995.
- Shi W, Wang Q, Zhao X and Zhao L: Study on the relationship between the mutations of hepatitis B virus X gene and precure gene, related factors and hepatocellular carcinoma. *Chinas Med* 8: 1673-4777, 2013 (In Chinese).
- Uchida T, Saitoh T and Shinzawa H: Mutations of the X region of hepatitis B virus and their clinical implications. *Pathol Int* 47: 183-193, 1997.
- Shinkai N, Tanaka Y, Ito K, Mukaide M, Hasegawa I, Asahina Y, Izumi N, Yatsushashi H, Orito E, Joh T, *et al*: Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2. *J Clin Microbiol* 45: 3191-3197, 2007.
- Cabibbo G, Antonucci M and Genco C: Update on new approaches in the management of hepatocellular carcinoma. *Hepat Med* 2: 163-173, 2010.
- Liu S, Zhang H, Gu C, Yin J, He Y, Xie J and Cao G: Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: A meta-analysis. *J Natl Cancer Inst* 101: 1066-1082, 2009.
- Takahashi K, Ohta Y, Kanai K, Akahane Y, Iwasa Y, Hino K, Ohno N, Yoshizawa H and Mishihiro S: Clinical implications of mutations C-to-T1653 and T-to-C/A/G1753 of hepatitis B virus genotype C genome in chronic liver disease. *Arch Virol* 144: 1299-1308, 1999.
- Tanaka Y, Mukaide M, Orito E, Yuen MF, Ito K, Kurbanov F, Sugouchi F, Asahina Y, Izumi N, Kato M, *et al*: Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. *J Hepatol* 45: 646-653, 2006.
- Wang Z, Tanaka Y, Huang Y, Kurbanov F, Chen J, Zeng G, Zhou B, Mizokami M and Hou J: Clinical and virological characteristics of hepatitis B virus subgenotypes Ba, C1 and C2 in China. *J Clin Microbiol* 45: 1491-1496, 2007.
- Kim HJ, Park JH, Jee Y, Lee SA, Kim H, Song BC, Yang S, Lee M, Yoon JH, Kim YJ, *et al*: Hepatitis B virus X mutations occurring naturally associated with clinical severity of liver disease among Korean patients with chronic genotype C infection. *J Med Virol* 80: 1337-1343, 2008.
- Choi CS, Cho EY, Park R, Kim SJ, Cho JH and Kim HC: X gene mutations in hepatitis B patients with cirrhosis, with and without hepatocellular carcinoma. *J Med Virol* 81: 1721-1725, 2009.
- Tangkijvanich P, Sa-Nguanmoo P, Mahachai V, Theamboonlers A and Poovorawan Y: A case-control study on sequence variations in the enhancer II/core promoter/precure and X genes of hepatitis B virus in patients with hepatocellular carcinoma. *Hepatol Int* 4: 577-584, 2010.
- Li W, Chen G, Yu X, Shi Y, Peng M and Wei J: Accumulation of the mutations in basal core promoter of hepatitis B virus subgenotype C1 increase the risk of hepatocellular carcinoma in Southern China. *Int J Clin Exp Pathol* 6: 1076-1085, 2013.
- Lyu H, Lee D, Chung YH, Kim JA, Lee JH, Jin YJ, Park W, Mathews P, Jaffee E, Zheng L, *et al*: Synergistic effects of A1896, T1653 and T1762/A1764 mutations in genotype c2 hepatitis B virus on development of hepatocellular carcinoma. *J Viral Hepat* 20: 219-224, 2013.

24. Huang X and Hollinger FB: Occult hepatitis B virus infection and hepatocellular carcinoma: A systematic review. *J Viral Hepat* 21: 153-162, 2014.
25. Lin CL, Chen JD, Liu CJ, Lee PH, Chen PJ, Lai MY, Kao JH and Chen DS: Clinicopathological differences between hepatitis B viral genotype B- and C-related resectable hepatocellular carcinoma. *J Viral Hepat* 14: 64-69, 2007.
26. Kay A and Zoulim F: Hepatitis B virus genetic variability and evolution. *Virus Res* 127: 164-176, 2007.
27. Yim HJ and Lok AS: Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005. *Hepatology* 43 (Suppl 1): S173-S181, 2006.
28. Jammeh S, Tavner F, Watson R, Thomas HC and Karayiannis P: Effect of basal core promoter and pre-core mutations on hepatitis B virus replication. *J Gen Virol* 89: 901-909, 2008.
29. Buckwold VE, Xu Z, Chen M, Yen TS and Ou JH: Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. *J Virol* 70: 5845-5851, 1996.
30. Yin J, Zhang H, Li C, Gao C, He Y, Zhai Y, Zhang P, Xu L, Tan X, Chen J, *et al*: Role of hepatitis B virus genotype mixture, subgenotypes C2 and B2 on hepatocellular carcinoma: Compared with chronic hepatitis B and asymptomatic carrier state in the same area. *Carcinogenesis* 29: 1685-1691, 2008.
31. Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, Wang LY, Lu SN, You SL, Chen DS, *et al*; REVEAL-HBV Study Group: Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. *J Natl Cancer Inst* 100: 1134-1143, 2008.